Plant Name: Phaseolus coccineus
Taxonomic Information:
Plant ID: NPO993
Plant Latin Name: Phaseolus coccineus
Taxonomy Genus: Phaseolus
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3886
Plant-of-the-World-Online:
513754-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
Bangladesh; Nepal; Ethiopia; Rwanda; Ecuador; Belarus; Guatemala; China; Ukraine; Tanzania; United States; Australia; New Zealand; Russia; Pakistan; Honduras; Mexico; South Africa; India; Uzbekistan; Colombia; Kenya; Nicaragua
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRB3; ADRA2A; ADRA2B; DRD2; | |
| TDP1; EIF4A1; APEX1; | |
| RELA; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | EIF4A1 | Eukaryotic initiation factor 4A-I | P60842 | CHEMBL2052028 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.739E-13 | 1.262E-09 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.533E-12 | 1.103E-08 | ADRA2A, ADRA2B, ADRA2C, ADRB3 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 9.992E-11 | 2.720E-07 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.996E-10 | 7.250E-07 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.996E-10 | 7.250E-07 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 5.588E-09 | 6.760E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 8.120E-08 | 6.549E-05 | ADRA2A, ADRA2C, ADRB3 |
| BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 4.457E-07 | 2.941E-04 | ADRA2A, ADRB3, DRD2 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 5.929E-07 | 3.489E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 2.410E-06 | 1.218E-03 | ADRA2A, ADRB3 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 2.869E-06 | 1.358E-03 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD2 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 3.367E-06 | 1.496E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.095E-05 | 7.601E-03 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.473E-05 | 8.823E-03 | ADRA2A, ADRA2C, ADRB3, DRD2, RELA |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.170E-07 | 7.959E-06 | ADRB3, ADRA2C, DRD2, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 9.470E-07 | 3.220E-05 | ADRB3, ADRA2C, ADRA2B, ADRA2A |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 2.613E-04 | 5.923E-03 | DRD2, RELA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | ADRB3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; ADRB3; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; ADRB3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD2; |
| NA: NA | Itching | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRB3; DRD2; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | ADRB3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; ADRB3; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB3; |
| NA: NA | False perceptions | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRB3; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| NA: NA | Hyperaemia | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; ADRB3; DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADRB3; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
